Roche announces FDA approval of Xofluza for the prevention of influenza following contact with an infected person
Basel, 24 November 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for Xofluza ® (baloxavir marboxil) as a treatment to prevent influenza in people 12 years of age and older following contact with someone with influenza (known as post-exposure prophylaxis). Xofluza is the first single-dose influenza medicine approved for post-exposure prophylaxis.“With today’s approval, Xofluza is now available as the first single-dose, post-exposure preventive treatment for influenza,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Development. “We’re hopeful that reducing the burden of influenza may he lp to mitigate the strain on our healthcare system amid the COVID-19 pandemic.” Post-exposure prophylaxis with single-dose Xofluza was evaluated in the phase III BLOCKSTONE study, which was recently published in The New England Journal of Medicine.1 BLOCKSTONE evaluated Xofluza compared with placebo as a preventive treatment for household members (adults and children) who were living with someone with influenza. Xofluza showed a statistically significant prophylactic effect on influenza after a single oral dose in people exposed to an infected household contact. The proportion of household members 12 years of age an...
Conclusions: A high serum CRP level on the initial day of TDM is an independent predictor of increasing vancomycin concentration-to-dose ratio in patients receiving intravenous vancomycin treatment, even if eGFR remains unchanged.
This study evaluated the effects of the CYP2D6*10 and CYP2D6*5 genotypes on the steady-state plasma concentrations of VEN and ODV in Japanese patients. Methods: This study included 75 Japanese patients with depression who were treated with VEN. Steady-state plasma concentrations of VEN and ODV were measured using liquid chromatography. Polymerase chain reaction was used to determine CYP2D6 genotypes. A stepwise multiple regression analysis was performed to analyze the relationship between independent variables (sex, age, smoking habit, and number of mutated alleles, CYP2D6*10 and CYP2D6*5), subject-dependent variabl...
Conclusions: After establishing an liquid chromatography with tandem mass spectrometry detection method for therapeutic drug monitoring of CAB, our analyses involving a single patient undergoing hemodialysis indicated that higher than expected doses of CAB were required to achieve reasonable plasma concentrations. Our study demonstrates the usefulness of therapeutic drug monitoring for the evaluation of “new” drugs in patients with renal impairment.
ConclusionsTrabectedin, in combination with PLD, may have clinical benefits in Japanese patients with relapsed advanced ovarian cancer. The recommended dosage of trabectedin for further study in this population is 1.1 mg/m2 once every 21 days.Clinical trial registration number: JapicCTI-163164
This study aimed to evaluate the correlation between clinicopathologic features and serum zinc levels in patients who underwent gastrectomy for gastric cancer.MethodsThe study enrolled 617 patients who underwent gastrectomy for gastric cancer at the Kochi Medical School. Clinical data were obtained to investigate associations between clinicopathological features, including nutritional indicators and serum zinc levels. Serum zinc deficiency was defined as serum zinc level
AbstractBackgroundA significant number of non-small cell lung cancer (NSCLC) patients develop osteogenic metastases (OMs) and/or brain metastases (BMs) after surgery, however, routine chest computed tomography (CT) sometimes fails to diagnose these recurrences. We investigated the incidence of BMs and OMs after pulmonary resection and aimed to identify candidates who can benefit from brain magnetic resonance imaging (MRI) and18F-fluorodeoxyglucose-positron emission tomography (FDG-PET) in addition to CT.MethodsWe retrospectively reviewed medical records of 1099 NSCLC patients who underwent pulmonary resection between 2002 ...
AbstractBackgroundThe prognosis of patients with recurrence of uterine cervical cancer after definitive radiotherapy and the efficacy of local salvage therapy for recurrence were evaluated.MethodsWe retrospectively reviewed 110 patients who were treated with definitive radiotherapy/chemoradiotherapy for uterine cervical cancer between 2008 and 2017 at our institution. Local salvage therapy was defined as any surgery or radiotherapy described in the medical record as intended for local control or cure.ResultsWe identified 25 patients who developed recurrence after definitive radiotherapy/chemoradiotherapy. The median follow...
ConclusionWhile the real-world overall survival in Japanese patients with mRCC in the targeted therapy era improved compared to that previously reported in the cytokine era, there was no clear difference in the survival of poor risk patients between these eras. There were no differences in the superiority among the models.
ConclusionsRM-1929 photoimmunotherapy showed a manageable safety profile in rHNSCC. Tumor response in these heavily pre-treated patients was clinically meaningful and warrants further investigation.Clinical trial registrationThe trial was registered with the Japanese registry of clinical trials as jRCT2031200133.
ConclusionsThere was no difference in OS between irinotecan and paclitaxel no in OS prolongation of S-1 combination therapy in second-line chemotherapy.
More News: Allergy & Immunology | Biotechnology | Bird Flu | Bird Flu (H5N1 Avian Influenza) Vaccine | Bronchitis | Cancer | Cancer & Oncology | Cancer in Adolescents | Cancer Vaccines | Child Development | Children | Coronavirus | COVID-19 | Diabetes | Diarrhoea | Endocrinology | Epidemics | Epidemiology | Flu Pandemic | Food and Drug Administration (FDA) | H5N1 | Headache | Infectious Diseases | Influenza | Influenza Vaccine | International Medicine & Public Health | Internet | Japan Health | Laboratory Medicine | Men | Migraine | New Drug Applications | Opthalmology | Oral Cancer | Oseltamivir | Pandemics | Pediatrics | Pharmaceuticals | Respiratory Medicine | SARS | Science | Sinusitis | Statistics | Study | Switzerland Health | Taiwan Health | Tamiflu | Urology & Nephrology | USA Health | Vaccines | WHO